Argus Upgrades Chemours On Significant Competitive Advantages

Loading...
Loading...

Argus's David Coleman upgraded Chemours Co CC to Buy with a $13.00 price target.

"We believe that Chemours has significant competitive advantages based on its large size, vertically integrated structure, and broad geographic reach," said Coleman. The company had shown strength by cutting costs and raising prices while improving working capital, according to the analyst.

Additionally, Coleman appreciated the CEO's positive comments on Chemours' recent transformation plan while projecting higher EBITDA and "modestly positive" free cash flow in FY16.

In response to Chemours' recent signs of strength, Argus raised the company's 2016 diluted EPS estimate from $0.75 to $0.83 and FY17 estimate from $1.087 to $1.16. Both estimates are above the analyst average.

According to TipRanks, Coleman has a 65 percent success rate and a +2.4 percent average return per recommendation.

At time of writing, Chemours traded at $10.67, up 3.59 percent.

date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorUpgradesPrice TargetAnalyst RatingsArgusDavid Coleman
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...